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Abstract Adenosine receptors are plasma membrane pro-
teins that transduce an extracellular signal into the interior
of the cell. Basically every mammalian cell expresses at
least one of the four adenosine receptor subtypes. Recent
insight in signal transduction cascades teaches us that the
current classification of receptor ligands into agonists,
antagonists, and inverse agonists relies very much on the
experimental setup that was used. Upon activation of the
receptors by the ubiquitous endogenous ligand adenosine
they engage classical G protein-mediated pathways, result-
ing in production of second messengers and activation of
kinases. Besides this well-described G protein-mediated
signaling pathway, adenosine receptors activate scaffold
proteins such as β-arrestins. Using innovative and sensitive
experimental tools, it has been possible to detect ligands
that preferentially stimulate the β-arrestin pathway over the
G protein-mediated signal transduction route, or vice versa.
This phenomenon is referred to as functional selectivity or
biased signaling and implies that an antagonist for one
pathway may be a full agonist for the other signaling route.
Functional selectivity makes it necessary to redefine the
functional properties of currently used adenosine receptor
ligands and opens possibilities for new and more selective
ligands. This review focuses on the current knowledge of
functionally selective adenosine receptor ligands and on G
protein-independent signaling of adenosine receptors
through scaffold proteins.
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Introduction
G protein-coupled receptors (GPCRs) are the most impor-
tant class of drug-targetable cell surface proteins [1]. These
receptors couple to several classes of heterotrimeric G
proteins consisting of Gα,G β, and Gγ subunits that are
activated upon receptor stimulation. Subsequently, the
heterotrimeric G protein dissociates into Gα and Gβγ
subunits, which on their turn activate intracellular targets.
There are at least four families of G proteins namely Gαi,
Gαs,G αq, and Gα12/13 that accommodate a variety of
combinations between the 16 different Gα,5G β, and 14
Gγ subunits [2]. Gαs and Gαi proteins activate or
inactivate adenylate cyclase (AC), respectively, resulting
in an increase or reduction of intracellular cyclic adenosine
monophosphate (cAMP) concentrations. Gαq proteins
activate phospholipase C (PLC) isoforms, resulting in for
instance formation of inositol phosphates and a raise in
intracellular Ca
2+ concentration. Activation of Gα12/13
proteins is associated with changes of the cytoskeleton.
The Gβγ subunits activate a broad variety of signal
transduction pathways upon their release, such as PLC,
AC, protein kinase D, c-Jun N-terminal kinase (JNK), the
non-receptor tyrosine kinase Src and phosphatidylinositol-
3-kinase (PI3K) and ion channels [2].
GPCRs consist of seven membrane-spanning α-helices
and are more and more often referred to as seven
transmembrane receptors (7TMRs). This is not merely
because of their membrane topology, but to account for
the observation that these receptors can activate a variety of
other proteins besides G proteins. The best studied G
protein-independent signal transduction pathway activated
by 7TMRs is the one mediated by β-arrestins. Upon
activation, 7TMRs are phosphorylated at their intracellular
domains by GPCR kinases (GRKs), followed by recruit-
ment and binding of β-arrestin-1 (also named arrestin-2),
β-arrestin-2 (also named arrestin-3), or the visual arrestins-
1 and −4[ 3–5].
Binding of β-arrestin functions as an off-switch for the
receptor by preventing interaction with G proteins and
mediates internalization of the receptor. Besides their role in
receptor desensitization and internalization, β-arrestins can
function as adapter or scaffold proteins that mediate G
protein-independent activation of, e.g., mitogen-activated
protein kinases (MAPKs) such as extracellular signal-
regulated kinases 1 and 2 (ERK1/2), Src, JNK, PI3K, or
the transcription factor NF-κB[ 6, 7].The MAPKs ERK1/2
are two signaling proteins where G protein-dependent and
β-arrestin-mediated pathways can converge. Activation of
ERK1/2 by 7TMRs occurs via a variety of pathways and is
often dependent on the cellular background in which such a
response is measured. G protein-dependent ERK1/2 activa-
tion is spatially and temporally distinct from β-arrestin-
mediated G protein-independent phosphorylation [6, 8].
ERK1/2 activation via G proteins often is rapid and
transient, while β-arrestin-mediated ERK1/2 phosphoryla-
tion is delayed and sustained. Furthermore, ERK1/2
activated by β-arrestins has been reported to remain
cytosolic, while ERK1/2 activated through G proteins is
localized in the nucleus in addition to the cytosol [8].
7TMRs can be divided in two classes dependent on their
interaction with β-arrestins: The first class binds β-arrestin-2
with higher affinity than β-arrestin-1, while the second class
of receptors binds both β-arrestins with equal affinity and
additionally binds visual arrestins [4]. While β-arrestin-1 and
visual arrestin are found in both the cytoplasm and nucleus
in the absence of an agonist in transfected human embryonic
kidney 293 (HEK293) cells, localization of β-arrestin-2 is
restricted to the cytoplasm [4]. Specific serine residues in the
C-terminal tails of 7TMRs were shown to determine
specificity for either β-arrestin-1 or β-arrestin-2. The
complexes of receptors of the first class with β-arrestins
were described to be relatively unstable and to readily
dissociate at or near the plasma membrane, while β-arrestins
bound to receptors of the second class were found to be more
stable and to internalize together into endocytic vesicles [4].
In addition, β-arrestin-1 and -2 were found to play different
roles in internalization but not desensitization or down-
regulation of 7TMRs [5].
It is likely that β-arrestin-1 and β-arrestin-2 fulfill distinct
and non-redundant functions in the cell, based on these
differences and their different tissue expression. On the other
hand, mouse knockout models of either β-arrestin-1 or
β-arrestin-2 show no gross phenotypes [3], while double
knockout mice die at birth [9]. This indicates that absence of
a β-arrestin isoform can be compensated for by the other
isoform, pointing to at least a certain level of redundancy
between the two proteins. Current knowledge from mouse
knockout models suggests that β-arrestin-2 plays a more
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β-arrestin-1 [3].
Functional selectivity
Many 7TMRs show promiscuous coupling to G proteins.
When a receptor activates more than one class of G
proteins, distinct conformations of the receptor may favor
coupling of one class of G proteins over another. Similarly,
when a 7TMR activates a G protein-independent β-arrestin-
mediated pathway in addition to G proteins, one pathway may
be preferred over the other, depending on the conformational
state of the receptor. Moreover, ligands that bind the receptor
may induce or stabilize receptor conformations that selectively
couple to a certain pathway, while leaving the other pathway
unaffected. These events are called functional selectivity or
biased signaling. The principles of functional selectivity have
been the subject of excellent and extensive reviews [10, 11].
Functional selectivity also implies that the concept of
ligandefficacyisveryassaydependent,sinceafullagonistfor
a certain pathway may be an antagonist, partial agonist or
inverse agonist for another pathway mediated by the same
receptor. Partial agonism and functional selectivity are two
separate phenomena that can produce overlapping responses.
It should therefore always be verified that apparent functional
selectivity between agonists is not merely caused by variation
in efficacy, since a high-efficacy agonist may activate more
Gα subtypes than a low-efficacy agonist. For example, a full
agonist for a given receptor may activate both Gαi and Gαq
proteins, while a partial agonist may activate the Gαi
pathway but may not be potent enough to activate Gαq
proteins as well. In this case, the partial agonist appears to
selectively activate the Gαi pathway, but this originates from
a general lack of efficacy at the receptor. Also differences in
receptor density between tissues may cause changes in
potency and efficacy of agonists. In a tissue expressing high
amounts of receptors, a partial agonist can become a full
agonist, a mechanism referred to as receptor reserve or spare
receptors. Likewise, if the ligand acts as a partial agonist on
the tissue with high expression levels of the receptor, it may
not be potent enough to elicit a response in a tissue
expressing less receptors. However, if agonist A is a full
agonist at Gαi and a partial agonist at Gαq, and agonist B
reversely shows partial agonism at Gαi and full agonism for
the Gαq-mediated pathway, a truly biased signal is observed.
Therefore, functional selectivity between agonists is only
detected if the rank order of efficacy or potency of the
agonists for two pathways is reversed.
The binding site of the natural ligand of a receptor is
referred to as the orthosteric binding site. Many receptors
are also capable of binding (synthetic) molecules or
proteins at sites different from the orthosteric site. These
sites are called allosteric binding sites, and the ligands are
named allosteric ligands. Allosteric ligands may be agonists
ontheir own right,ormodulatethe signaling of the orthosteric
ligand, in which case they are called positive or negative
allosteric modulators, PAMs and NAMs, respectively (for
reviews on allosteric modulation of 7TMRs in general see
references[11, 12]a n df o ra l l o s t e r i cm o d u l a t i o no fa d e n o s i n e
receptors in particular see references [13, 14]). Allosteric
ligands induce or stabilize specific receptor conformations,
thereby changing the active state of the receptor and/or the
mode the orthosteric ligand interacts with the receptor. This
can be seen as fine-tuning of the receptor and its response.
Even binding of a G protein or other protein to the
intracellular domains of a 7TMR can be seen as allosteric
modulation, since this interaction stabilizes a certain (active)
state of the receptor and influences binding of the orthosteric
ligand. Since both orthosteric and allosteric ligands induce
specific receptor conformations, interplay between both can
be envisioned, so that an allosteric modulator can induce or
enhance functional selectivity of an orthosteric ligand.
From a drug development point of view, the possibility
to activate one pathway while leaving other pathways
untouched offers unique possibilities with respect to
selectivity and the prevention of side effects. For instance,
the use of nicotinic acid to lower triglycerides and raise
high-density lipoproteins is hampered by the adverse effects
of cutaneous flushing, burning, and itching, since all these
effects are mediated by the hydroxy-carboxylic acid
receptor HCA2 (also named GPR109A). It seems however
that cutaneous flushing is mediated by a β-arrestin-
dependent pathway, while the anti-lipolytic effect is not
[15]. Interestingly, a synthetic compound called MK-0354
lacks the vasodilatory effects responsible for skin flushing,
but retains the anti-lipolytic signaling in vivo [16]. Indeed,
MK-0354 was found to activate G protein-dependent
pathways, but not β-arrestin signaling [15, 16], indicating
that it is possible to separate desired and unwanted effects
using functionally selective drugs. This is only one example
out of many: several other receptors for which a bias
between G protein-dependent and β-arrestin signaling
pathways has been described, such as the β1-and β2-
adrenergic receptors, the μ-opioid receptor, the dopamine
D2 receptor (D2R), serotonin receptors 5-HT2A and 5-HT2C,
the angiotensin AT1A receptor, the chemokine CXCR4
receptor and the parathyroid hormone type 1 receptor have
been recently reviewed [6].
MembersoftheJNKMAPKfamilyhavebeenshowntobe
important mediators of biased signaling events at opioid
receptors [17]. It has been known for some time that a class
of μ-opioid ligands, including morphine, does not induce
robust phosphorylation and internalization of the receptor, in
contrast to other ligands such as endogenous enkephalins.
Ligand-directed JNK activation was found to block G
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involved in long-term inactivation of the κ-opioid receptor as
well as acute analgesic tolerance of the μ-opioid receptor [17].
The mechanism leading to ligand-directed JNK activation is
presently unknown but may involve β-arrestins. Nevertheless,
JNK could represent a novel mediator of functionally selective
responses for GPCRs in general.
Most research regarding functional selectivity has focused
on selective activation of different classes of G proteins, or
biased activation of β-arrestins versus G proteins. However,
besides β-arrestins, 7TMRs interact with a variety of other
intracellular scaffold proteins. Scaffold proteins can link the
7TMR to one or more other effectors, thereby facilitating
efficient signal transduction by bringing all partners together
in the same signaling complex. Scaffold proteins for instance
can physically interact with proteins such as ERK1/2, Src,
JNK, PLC, protein kinase A (PKA), ADP-ribosylation factor-
nucleotidesiteopener(ARNO)andactin(seereference[7]f o r
a review). Src, which is important in several signaling
cascades leading to ERK1/2 phosphorylation, has even been
shown to be directly activated by the β2-adrenergic receptor
[18]. Theoretically, scaffold proteins can stabilize receptor
conformations that lead to functional selectivity. In practice,
however, it will often be difficult to experimentally separate
scaffolding functions from the allosteric effects induced by
scaffold proteins [7].
Many scaffold proteins contain one or more PDZ (post-
synaptic density protein 95/Discs-large/Zo-1 protein) motifs
that interact with the distal part of the carboxyl terminus of
7TMRs. While phosphorylation of 7TMRs by GRKs often
leads torecruitmentofβ-arrestins, phoshorylation of serine or
threonine residues in a PDZ domain can prevent the
association of a receptor with a scaffold protein [7].
Phosphorylation of 7TMRs by specific GRKs appears to be
crucial for some biased responses, such as those elicited by
the endogenously expressed chemokines CCL19 and CCL21
upon binding to the chemokine receptor CCR7. Although
both ligands have comparable binding affinities and activate
G protein-dependent pathways with equal potency, CCL19
but not CCL21 induced robust phosphorylation, β-arrestin-2
recruitment, and CCR7 desensitization [19]. In addition,
CCL19-mediated ERK1/2 activation was partially mediated
by β-arrestin-2. On the other hand, ERK1/2 activation was
found to be completely dependent on Gαi activation. This
suggests that CCL19-induced β-arrestin recruitment is
triggered by phosphorylation of CCR7 by GRKs, which
are activated in a Gαi-dependent manner. Indeed, it was
found that activation by CCL19 or CCL21 leads to
differential GRK specificity for CCR7 [20]. In this study,
CCL19 induced robust phosphorylation of CCR7 and
recruitment of β-arrestin-2 catalyzed by both GRK3 and
GRK6, whereas CCL21 mediated phosphorylation and
recruitment of β-arrestin-2 was less pronounced and in-
volved only GRK6. However, solely CCR7 phosphorylation
and β-arrestin-2 recruitment by CCL19 resulted in traffick-
ing of CCR7 to endocytic vesicles and receptor desensitiza-
tion. Both chemokines stimulated ERK1/2 involving GRK6
but not GRK3. Interestingly, GRK6 but not GRK3 is also
important for β-arrestin-mediated ERK activation by
β2-adrenergic receptors, indicating that this may be a
common mechanism [8]. It has been suggested that GRK-
specific phosphorylation patterns of the receptor may be
interpreted as a “barcode” that instructs adapter proteins such
as β-arrestins which conformation to adapt, and therefore
which scaffolding functions to perform [20]. Such a GRK-
induced barcode would also confer specificity to the many
possible interactions with the wide range of scaffold proteins
that have been described for 7TMRs.
Adenosine receptors
Four 7TMRs for the endogenous molecule adenosine 1
have been described, named adenosine receptor A1 (A1R),
adenosine receptor A2A (A2AR), adenosine receptor A2B
(A2BR), and adenosine receptor A3 (A3R; see Fig. 1 for
structures of the ligands mentioned in this review) [21]. The
best-known antagonist for A1Ra n dA 2Rs u b t y p e si s
caffeine, the active ingredient of coffee and tea. The
adenosine A1R and A2AR are highly expressed in the brain,
where adenosine is involved in sleep/wakefulness and
modulation of neurotransmitter responses [21, 22]. A1Rs
interact with various neurotransmitter systems such as
dopamine D1 and N-methyl-D-aspartate (NMDA) receptors,
while A2AR and D2R-mediated signaling are closely linked.
In the periphery, A1Rs are expressed in adipose tissue and
the atria of the heart where they are involved in for instance
inhibition of lipolysis and bradycardia. In addition to the
brain, A2ARs are highly expressed on leukocytes and
platelets. A2BRs are ubiquitously expressed at low levels
and found in higher levels in the intestine and bladder [21,
22]. Using an A2BR-knockout/reporter-gene knock-in
mouse model, it was shown that the primary site of A2BR
expression is the vasculature [23]. In addition to the
vasculature, A2BR-gene promoter activity was high in
macrophages [23]. The A3R is found in lung, liver, and
other peripheral tissues, the brain, as well as on eosinophils
and mast cells [21, 24].
Adenosine is present in all cells and extracellular fluids.
During episodes of oxidative stress, ischemia and hypoxia
the levels of adenosine increase, and activation of adeno-
sine receptors is thought to play a protective role. Due to
the broad expression of adenosine receptor subtypes, and
the omnipresence of the endogenous agonist adenosine,
selectivity of synthetic therapeutic adenosine ligands is very
important. Such selectivity may sometimes be reached with
174 Purinergic Signalling (2011) 7:171–192receptor subtype-specific compounds (see references [14, 25]
for an overview of adenosine receptor ligands), but becomes
problematic if the same receptor mediates different physio-
logical processes. However, if different processes downstream
of the same receptor are involved in a pathological condition,
biased compounds would have the potential to selectively
activate the therapeutically relevant pathway without affecting
other signal transduction routes. Moreover, since an antagonist
for a G protein-mediated response can still be an agonist for
β-arrestin-mediated signaling, it is important to know if a
drug shows functional selectivity in order to predict and
prevent adverse effects.
Adenosine receptors are tightly regulated in terms of
desensitization and internalization, mediated by GRKs
and β-arrestins (reviewed in [24]). It is therefore not
improbable that biased adenosine receptor ligands exist,
which selectively activate β-arrestin-mediated signal
transduction pathways. Adenosine receptors have been
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Purinergic Signalling (2011) 7:171–192 175reported to activate ERK1/2i nav a r i e t yo fc e l lt y p e s ,
mediated by different downstream signaling components [26,
27]. Since both G protein-dependent and -independent
pathways often come together at the level of ERK1/2, some
special attention to this MAPK will be dedicated in the
paragraphs below describing the individual adenosine
receptors.
Dimerization and oligomerization of 7TMRs can also be
seen as allosteric modulation of the receptor and often
results in modified binding and signaling properties
compared to the monomeric receptor. Homo- and hetero-
dimerization of adenosine receptors have recently been
reviewed [14, 28] and a complete overview would be
beyond the scope of the current review.
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A1Rs couple to Gαi(1–3) proteins and Gαo, and their main
effects are thought to be through the inhibition of intracellular
cAMP levels [29]. In addition, release of βγ-subunits from
pertussis toxin (PTX)-sensitive Gαi proteins can result in the
activation of PLC isoforms, followed by formation of inositol
phosphates and diacylglycerol, and release of Ca
2+ from
intracellular stores [30]. The A1R activates ERK1/2 in
Chinese Hamster Ovary (CHO) cells as well as in a variety
of other cell types [26, 27].
Functional selectivity of A1 adenosine receptors
Besides the prototypical coupling of A1Rt oG αi proteins,
activation of Gαq and Gαs proteins [31]a sw e l la s
promiscuous Gα16 proteins [32] has been reported (Fig. 2).
The non-selective agonist NECA 8 and the A1R-selective
agonists CPA 5 and R-PIA 7 were tested for their ability to
stimulate Gαs and Gαq proteins after inactivation of Gαi
proteins with PTX [31]. The experiments were performed
in CHO cells expressing low (CHO-A1-low) and high
(CHO-A1-high) amounts of the A1R. In PTX-treated CHO-
A1-low cells, NECA enhanced forskolin-induced cAMP
accumulation, while CPA and R-PIAwere unable to activate
Gαs proteins. In the cells with high A1R expression levels all
three agonists induced cAMP formation, indicating that
NECA has a higher intrinsic efficacy for the Gαs pathway
than CPA and R-PIA. Indeed, in the CHO-A1-high cells
NECA was the most efficacious agonist in stimulating Gαs-
mediated cAMP accumulation compared to the other
agonists, although it had the lowest potency. Similar to
stimulation of Gαs proteins, NECA showed higher efficacy
than CPA and R-PIA for PTX-insensitive Gαq-mediated
inositol phosphates formation, again while having lower
potency. The efficacies of the agonists for the traditional
Gαi-mediated pathway were similar, and potencies found for
Gαi-activation were approximately 200- to 1,200-fold higher
than for Gαs-mediated signal transduction and 1,700- to
20,000-fold higher than for Gαq-mediated inositol phos-
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levels in this model, likely forcing the receptor to couple to
G proteins which may not be activated in a more
physiological setting, it appeared that NECA has a higher
intrinsic activity for Gαq and Gαs than CPA en R-PIA
(Fig. 2). In a follow-up study, a series of NECA and CPA
analogs was tested in order to elucidate the structure-activity
relationship underlying this functional selectivity [33]. All
tested compounds were full agonists in the Gαi-mediated
inhibition of cAMP. Interestingly, the NECA-analog CPeCA
9, bearing a cyclopentyl instead of an ethyl group at the 5′-
N-position of NECA, showed higher efficacy for the Gαs
p a t h w a yt h a nf o rt h eG αq pathway. Binding of NECA to the
A1R is crucially depending on threonine residue T7.42
(T277) in TM7, as mutation of this residue abolishes binding
for NECA, but not for R-PIA (7TMR numbering according
to reference [34]). R-PIA 7 has an intact ribose group and is
less efficacious in activating Gαq and Gαs than NECA 8.
Therefore interaction of the 5′-N-substituents of NECA 8 and
CPeCA 9 with T7.42 may be involved in functional
selectivity towards PTX-insensitive pathways.
The A1R-selective CPA-analog CHA 6, which has a
cyclohexyl instead of a cyclopentyl group at the N
6-
position of adenosine, was more efficacious than CPA 5
in activating Gαs and Gαq, indicating that substitution at
this position may induce functional selectivity too. This
hydrophobic N
6-moiety has been suggested to interact with
amino acids in the TM3 domain of the receptor such as
L3.33 (L88) and to confer A1R-selectivity to ligands [35].
Differential interaction of the N
6-cyclopentyl or cyclohexyl
group of CPA 5 and CHA 6 with L3.33 may therefore
underlie the observed differences in efficacy by stabilizing
different receptor conformations.
That PTX-insensitive pathways can be physiologically
relevant is illustrated by the A1R-mediated activation of the
transcription factor NF-κB by CHA, through proteins of the
promiscuous Gα16 class in the human lymphoblastoma Reh
cell line [36]. Gα16 proteins are mainly expressed in
hematopoietic cells and the agonist-dependent differences
in efficacy between PTX-sensitive and PTX-insensitive
responses described above raise the question if functionally
selective compounds can be designed that specifically
target these Gα16-mediated pathways.
A series of 4-substituted 2-amino-3-benzoylthiophenes
(2A3BTs) was tested for their ability to act as allosteric
enhancers of ERK1/2 activation by the orthosteric A1R-
selective ligand R-PIA [37]. Two compounds showed
allosteric enhancement of R-PIA-induced ERK1/2 activation,
as well as partial agonism in the absence of R-PIA. These
compounds, with 3-trifluoromethylphenyl 10 [38] and 3,5-
di-trifluoromethylphenyl 11 substituents of the 4-position,
were additionally tested in a [
35S]GTPγS binding assay.
Using an operational model of allosterism it was calculated
that the 3-trifluoromethylphenyl substituted compound 10
showed a significant difference in positive cooperativity
between enhancement of R-PIA-induced ERK1/2 activation
and [
35S]GTPγS binding. The authors suggested that this
allosteric enhancer displays functional selectivity with
respect to the amount of allosteric potentiation, depending
on the pathway that is investigated.
The observation that the 2A3BT-class of allosteric
enhancers may bias the signaling of the orthosteric ligand
towards a certain signal transduction pathway was further
investigated with another panel of allosteric modulators,
i.e., T62 12,V C P 5 2 013, and VCP333 14 [39]. All
allosteric compounds acted as partial agonists for ERK1/2
activation and for inhibition of cAMP accumulation in the
absence of the orthosteric agonist R-PIA in intact CHO
cells, except for VCP333 which was almost devoid of
ERK1/2 signaling. The compounds were inactive in an
intracellular Ca
2+ mobilization assay in the absence of R-
PIA. Surprisingly, while the potency of the orthosteric
Gαq/11 
Gαi 
Gαs 
ERK1/2
A1 
NECA 
allosteric 
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Hsc73
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4.1G
-arrestin
A1 
CPA  R-PIA 
CHA  CPeCA 
Fig. 2 Functional selectivity of the adenosine A1 receptor. The A1Rc a n
activate Gαs and Gαq/11 proteins besides the classical Gαi pathway. The
non-selective agonist NECA has higher intrinsic activity for these
alternative pathways than A1R-selective agonists. The intrinsic activities
of A1R-selective agonists such as CHA, CPA,a n dCPeCA for the
alternative G proteins differ amongst each other as well. Allosteric
modulators such as 2A3BT-class PAMs can bias signaling of orthosteric
ligands. The endogenous enzyme ADA appears to function as a natural
extracellular allosteric modulator of A1Rs, possibly in close cooperation
with the intracellular scaffold protein Hsc73. Signaling through G
proteins and β-arrestins converges at the level of ERK1/2 activation.
Interaction with scaffold proteins like 4.1G protein may favor functional
selectivity by stabilizing distinct receptor conformations. See references
in the text for more detailed information
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than for inhibition of cAMP, the opposite was true for the
allosteric partial agonists that were more potent for the
inhibition of cAMP than for ERK1/2 activation. This is a
typical example of functional selectivity and indicates that the
allosteric ligands bias A1R signaling towards different path-
ways than R-PIA, by stabilizing different receptor conforma-
tions compared to the orthosteric ligand. When tested in the
presence of R-PIA, the allosteric compounds enhanced the
potency of R-PIA-mediated signaling and in addition
increased the efficacy for Ca
2+ mobilization. Using the
operational model of allosterism, it was calculated that the
VCP520-mediated potentiation of R-PIA signaling in the Ca
2+
mobilization assay was significantly greater than for ERK1/2
activation, again pointing towards functional selectivity.
VCP520 13 differs only in one atom from the above-
mentioned 3-trifluoromethylphenyl substituted 2A3BT 10
[37] (i.e., a chloro vs. a hydrogen at the 4-position of the
benzoyl group), suggesting that the 3-trifluoromethylphenyl
substituent of the 2A3BT may be of importance for functional
selectivity of 2A3BTs. The same laboratory also observed that
the 2A3BT class of allosteric modulators has a receptor-
independent effect as inhibitors of an intracellular component
at the level of G proteins, when used at higher concentrations
in membrane preparations but not in intact cells [39]. This
finding indicates that care must be taken in the choice of assay
used to determine the effects of 2A3BTs.
β-arrestins
In addition to coupling to G proteins, A1Rs can interact with
several other proteins, raising the possibility to signal through
G protein-independent pathways (Fig. 2). Interaction of
GPCRs with β-arrestins is one of the best-described path-
ways through which ligands may demonstrate functional
selectivity. Upon stimulation of the A1R with the A1R-
selective agonist R-PIA in CHO cells, β-arrestin-2 was
redistributed from the cytoplasm to punctuate spots located
near the plasma membrane [40]. Surprisingly, no internaliza-
tion of A1R was detected, and there was no significant
overlap between the localization of A1Ra n dβ-arrestin-2. On
the other hand, knock-down of β-arrestin-1 in Syrian hamster
ductus deferens smooth muscle tumor (DDT1 MF-2) cells
almost completely abrogated downregulation of the A1R
upon 24-h stimulation with R-PIA [41]. Short-term stimula-
tion of DDT1 MF-2 cells with R-PIA resulted in a rapid
translocation of β-arrestin-1 to the membrane. Stimulation of
these cells with R-PIA also resulted in a rapid and transient
ERK1/2 activation, which was abolished after knock-down of
β-arrestin-1, indicating that A1 can activate ERK1/2 via β-
arrestin-1. This is in contrast with the observation that ERK1/
2 activation by β-arrestin often results in a sustained second
phase of ERK1/2 phosphorylation [6, 8]. Nevertheless, this
β-arrestin-mediated activation of ERK1/2 is of particular
interest since ERK1/2 activation may be important for the
cardioprotective effect mediated by A1Rs during ischemia/
reperfusion [42–44]. Agonists for the A1R that show
functional selectivity for the β-arrestin/ERK pathway may
therefore be useful for cardioprotection, provided that β-
arrestin-mediated ERK activation indeed is part of the
mechanism of cardioprotection. This may not be the case,
as ERK1/2 activation in rat cardiomyocytes was shown to be
completely sensitive to treatment with PTX, and was
suggested to involve βγ-subunits from Gi proteins,
genistein-sensitive Src tyrosine kinases, PKC, and PLC
instead of β-arrestins [44].
Although A1R-mediated ERK1/2 activation has been
shown to be dependent on either G proteins or β-arrestins,
no biased ligands have been reported that favor one
pathway over the other.
Internalization by adenosine A1 receptors antagonists
Ligand-induced internalization of GPCRs can occur indepen-
dently of G protein activation, for instance by stabilizing
receptor conformations that promote β-arrestin recruitment
and internalization. Both the agonist R-PIA and the A1R
antagonist/inverse agonist DPCPX 15 induced internalization
of A1Rs in rat GH4 pituitary cells [45]. In contrast,
incubation of DDT1 MF-2 cells with R-PIA resulted in
downregulation, while DPCPX induced upregulation of
A1Rs [46]. The upregulation of A1Rs by the inverse
agonist/antagonist DPCPX in DDT1 MF-2 cells can be
explained by stabilization of the receptor and is more often
observed for inverse agonists [47]. However, the observed
downregulation by the inverse agonist/antagonist DPCPX in
rat GH4 cells suggests a G protein-independent mechanism,
indicating that DPCPX may display functional selectivity
through for instance β-arrestin-mediated pathways.
Full agonists versus partial agonists
A different method of reaching tissue-selective effects of A1R
agonists has been through the use of partial agonists instead
of full agonists. Agonists of A1Rs may be useful in the
treatment of non-insulin-dependent diabetes mellitus because
of their anti-lipolytic effects. However, the expression of
A1Rs in the body is widespread and selective anti-lipolytic
action seems to be hard to obtain. More importantly,
stimulation of A1Rs in the heart by full agonists can lead
to adverse cardiovascular effects such as severe bradycardia
and AV block. In order to be useful in the treatment of non-
insulin-dependent diabetes mellitus, the cardiac side effects
have to be separated from the anti-lipolytic properties.
Interestingly, several 8-alkylamino-substituted analogs of
the agonist CPA 5 showed less-pronounced decreases in
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tested in vivo in rats, acting as partial agonists on these
responses [48]. When these CPA analogs were tested for
their anti-lipolytic effects in vivo, it was found that they
reduced lipolysis to levels which were almost comparable to
the full agonist CPA, although they are partial agonists with
respect to lowering the heart rate [49]. The selectivity
between bradycardia and anti-lipolytic effect was dependent
on differences in potency and intrinsic activity of the CPA
analogs for the two effects. This intriguing finding was
explained by the difference in receptor reserve between heart
tissue and adipose tissue. Depending on the amount of
receptors present in a tissue and their efficiency in coupling
to a certain intracellular response, low-efficacy agonists can
act as full agonists, partial agonists, or antagonists. There-
fore, it is possible to develop anti-lipolytic effects without
severe cardiovascular effects, making use of the fact that
receptor reserve in adipose tissue is higher than in cardiac
tissue [49]. Similarly, the negative effects of A1Ra g o n i s t so n
the cardiovascular system hamper the development of A1
agonists as potential antiarrhythmic drugs. It has been
suggested that this problem can be overcome by the
development of partial A1R agonists, which may moderately
slow AV conduction time and control ventricular rate during
periods of atrial tachycardias, without causing serious
cardiovascular side effects. For instance, CVT-2759 16 was
identified as a partial agonist compared to the full agonist
CPA 5 for slowing AV nodal conduction in guinea pig
isolated hearts, without causing AV block or severe slowing
of atrial rate [50]. This effect is also attributed to the
relatively low expression of A1Rs in the heart, resulting in an
absence of receptor reserve. Indeed, when tested in Fisher rat
thyroid (FRTL-5) cells or rat epididymal adipocytes which
have higher A1R expression, CVT-2759 acted as a full
agonist [50]. These results indicate that partial A1Ra g o n i s t s
may also be useful as antiarrhythmic drugs. The tissue-
selective effects of partial agonists described in this
paragraph should not be mistaken for functional selectivity,
as the observed selectivity solely relies on differences in
receptor density between tissues.
Indications of functional selectivity at adenosine A1 receptors
There are some additional indications that A1Rs have the
potential to direct extracellular signals to specific pathways.
For instance, overexpression of G protein-coupled receptor
kinase 2 (GRK2) inhibited Gβγ-mediated ERK1/2 activation,
but not Gαi-mediated inhibition of cAMP in FRTL-5 cells
[51]. Expression of GRK2-K
220R, a kinase-dead dominant
negative mutant of GRK2, did not influence ERK1/2
activation or cAMP reduction, indicating that the regulation
of ERK1/2 activity was not due to βγ-scavenging by GRK2.
It was suggested that the differential regulation of ERK1/2
and cAMP is due to the ability of GRK2 to phosphorylate the
A1R in a manner that affects Gβγ-mediated signaling but not
Gαi-mediated signaling. Adenosine and CPA were used as
agonists in this study, and it would be interesting to see if
other ligands would be able to influence this GRK2-mediated
bias in signaling.
Another example of an endogenous protein that can
influence A1R signaling is the ectoenzyme adenosine
deaminase (ADA) which breaks down adenosine into inosine
(Fig. 2). This enzyme is often added to in vitro studies with
adenosine receptors in order to prevent effects of endogenous
adenosine. ADA interacts directly with the A1R in pig brain
cortical membranes and DDT1 MF-2 cells and interestingly
the interaction of ADA with an extracellular domain of the
A1R is necessary to induce the G protein-coupled high-
affinity state of the receptor [52, 53]. Human ADA was
shown to increase both agonist and antagonist binding on
human brain striatal membranes, and to act as a positive
allosteric modulator by increasing the potency of R-PIA
more than tenfold in CHO cells [54]. While ADA increases
binding of agonists and antagonists to the A1R, it was shown
to decrease binding of the pig A1R to the heat shock cognate
protein Hsc73 [55]. Hsc73 by itself reduces binding of the
agonist R-PIA and the A1R-selective inverse agonist DPCPX
and reduces activation of G proteins through an interaction
with the third intracellular loop of the A1R[ 55]. The Hsc73-
mediated reduction in binding of R-PIA and DPCPX could
be reversed by addition of ADA. Since ADA binds to an
extracellular domain [53] and Hsc73 to the third intracellular
loop, it was suggested that binding of ADA affects the
structure of the third intracellular loop, thereby inhibiting
binding of Hsc73 [55]. If Hsc73 acts as an inhibitor of ligand
binding to the A1R, the release of Hsc73 upon incubation
with ADA may explain the positive effects that ADA has on
ligand affinity and potency. Both proteins appear to be
involved in internalization processes of the receptor. ADA
enhanced and accelerated R-PIA-induced phosphorylation of
the A1R and increased the rate of desensitization and
internalization [56]. In addition, ADA colocalizes with the
A1R on the plasma membrane and in intracellular vesicles
upon R-PIA-induced internalization. Hsc73 also colocalizes
with the A1R on the plasma membrane, but upon internal-
ization into intracellular vesicles, Hsc73 is only found
together with the A1Ri ns o m eo ft h eA 1R-containing
vesicles. The authors suggested that binding of ADA to the
extracellular domain of the A1R may prevent association of
Hsc73 during sequestering into intracellular vesicles, result-
ing in different A1R trafficking depending on the presence of
ADA or Hsc73. Hsc73 is also involved in internalization of
the chemokine receptor CXCR4, and knock-down of Hsc73
inhibits CXCR4-mediated chemotaxis without affecting
ligand binding, indicating the potential regulation of signal-
ing pathways by this heat shock protein [57]. It is unknown
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allosteric modulators, can bias signaling of orthosteric A1R
agonists towards a preferred intracellular pathway, analogous
to the synthetic allosteric modulators of the 2A3BT class
described above.
Upon stimulation of the A1R with R-PIA in pig kidney
epithelial LLC-PK cells, the A1R and ADA aggregate on the
cell surface and translocate into intracellular compartments
[58]. In these intracellular vesicles, the A1R was found to
colocalize with caveolin and to interact with caveolin-1
through its C-terminal domain. Caveolins are an important
component of caveolae, which are microdomains in the cell
membrane that orchestrate signal transduction and receptor
trafficking. Further interactions of the A1R with caveolins
have been reported for caveolin-1 [59] and caveolin-3 [60].
Interaction of the A1R with proteins of the caveolin family
implies localization of A1Rs in these microdomains, where
they can activate caveolae-specific pathways that may not be
available in other subcellular compartments, for instance
regulation of ATP-sensitive K
+ channels [60]. Surprisingly,
A1Rs have been shown to leave caveolae upon activation by
agonists [61]. Caveolae contain members of the MAPK
family as well, and besides interacting with the A1R,
caveolin-3 interacts directly with ERK2 but not ERK1 in
rat cardiomyocytes [62]. The A1R agonist CCPA stimulated
phosphorylation of both ERK1 and ERK2 in cytosolic
fractions of these cells, whereas in caveolin-3 enriched
fractions phosphorylation of ERK2 was reduced and
phosphorylation of ERK1 was unchanged.
In a yeast two-hybrid screen an interaction of the third
intracellular loop of the rat A1R with the cytoskeletal 4.1G
protein was identified [63]( F i g .2). Colocalization of A1Rs
and 4.1G was shown in the mouse cerebral cortex microglia
as well [64]. Cotransfection of the rat A1R and 4.1G protein
in HEK293 cells resulted in a remarkable loss of binding of
the inverse agonist [
3H]-DPCPX, observed as a 40-fold
lower Bmax and almost 60-fold increase in Kd compared to
cells expressing the A1R alone. The ability of the agonist
CPA to inhibit forskolin-induced cAMP accumulation in
CHO cells cotransfected with 4.1G protein was reduced by
approximately 50%, whereas mobilization of intracellular
Ca
2+ by CPA was completely abolished. This suggests that
binding of 4.1G to the A1R affects calcium mobilization
more than cAMP inhibition, and may indicate that the 4.1G
protein induces functional selectivity for CPA. However,
these differences may also arise from the type of assay or
concentration of CPA that was used in the assays. Altogether,
these findings demonstrate that the localization of A1Rs in
subcellular compartments such as caveolae can contribute to
activation of specific pathways (such as K
+ channels) and to
differential regulation of ERK1/2. Scaffolding proteins such
as caveolins or 4.1G may also stabilize conformations of the
receptor that may be preferred by some ligands over other
confirmations, thereby inducing functional selectivity.
However, such ligands have yet to be identified.
A2A adenosine receptors
The A2AR is coupled to Gαs and Golf proteins [65, 66], but
h a sa l s ob e e nr e p o r t e dt oi n t e r a c tw i t hh e m a t o p o i e t i cG α15/16
proteins [67]( F i g .3). Activation of ERK1/2 in CHO cells
expressing the A2AR is biphasic and less pronounced than
activation mediated through the Gαi-coupled A1Ro rA 3R
[27, 68]. The mechanism of ERK1/2 activation by A2ARs
was compared between transfected HEK293 and CHO cells
and appeared to be highly cell-type dependent [26, 69]. In
CHO cells, A2AR-mediated ERK1/2 activation was Gαs-
dependent, while in HEK293 cells Gαs-, Gαi-, and PKC-
independent ERK1/2 activation was observed that required
p21
ras [69, 70]. It was suggested that A2ARs may couple to
Gα12/13 proteins in HEK293 cells, or activate ERK1/2
through G protein-independent pathways. ERK1/2 activation
by the A2AR/A3R-selective agonist CGS21680 17 in CHO
cells was shown to be mediated via a Gαs/cAMP/PKA/Src-
like kinase dependent pathway [68]. Hepatic stellate cells
(HSC) play an important role in the pathogenesis of hepatic
G 15/16 
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Fig. 3 Potential for functional selectivity of the adenosine A2A receptor.
Although no functionally selective ligands for the A2AR have been
identified to date, this adenosine receptor in particular bears potential for
biased signaling. Its exceptionally long carboxyl terminus interacts with
a variety of scaffold proteins such as β-arrestins, α-actinin, ARNO,
calmodulin, NECAB2, USP4,a n dTRAX. Besides the classical activation
of Gαs proteins by A2ARs, interaction with Ga15/16 proteins of the Gαq/
11 family has been reported. Both G protein-dependent and -independent
pathways can lead to phosphorylation of ERK1/2 by A2AR. Several
lines of research indicate that interaction with scaffold proteins tethers
A2ARs to microdomains in the plasma membrane, where they may
engage selective signal transduction pathways. See references in the text
for more detailed information
Purinergic Signalling (2011) 7:171–192 181fibrosis and cirrhosis because they produce matrix proteins
such as collagen after activation. Collagen type I expression
by HSC upon stimulation of A2AR with CGS21680 was
shown to be regulated by a pathway involving PKA, Src,
and ERK1/2, whereas collagen type III depended on
activation of p38 MAPK but not PKA, Src, and ERK1/2
[71]. It is not known at which level the ERK1/2 and p38
pathways activated by the A2AR start to diverge. If they
diverge at the level of the A2AR itself, it may be possible to
selectively activate either the ERK1/2 or p38 with biased
ligands in these cells.
In contrast to the other adenosine receptors, which have
C-terminal tails of about 30–40 amino acids, the carboxyl
terminus of the A2AR consists of 122 amino acids. This long
C-terminal tail offers the opportunity to interact with many
intracellular proteins that may stabilize receptor conformations
required for functional selectivity or mediate G protein-
independent signaling. There is a rapidly expanding list of
proteins that have been shown to interact with the C-terminus
of the A2AR including α-actinin [72], ARNO/cytohesin-2
[73], the de-ubiquinating enzyme ubiquitin-specific protease 4
(USP4) [74], translin-associated protein X (TRAX) [75],
neuronal Ca
2+-binding protein 2 (NECAB2) [76], and
calmodulin [77]( F i g .3). In addition, a recent review about
proteins that interact with the A2AR C-terminus describes
neuroendocrine-discs large homolog 3/synapse-associated
protein 102 (NE-DLG/SAP102), 14.3.3 protein-θ/τ and astrin
as candidate proteins [78]. Translocation of β-arrestin-1 and
β-arrestin-2 upon stimulation of transfected HEK293 cells
with the agonist CGS21680 indicates that the A2AR interacts
with β-arrestins as well [72].
The importance of the C-terminus for the activation of
distinct signal transduction pathways was shown using
C-terminallytruncatedversionsofthereceptor[79]. Truncation
of the A2AR blunts constitutive cAMP formation in intact
HEK293 cells, but leaves ERK1/2 activation unaffected.
When using membranes instead of intact cells, no differences
in constitutive G protein activation could be observed between
WT and truncated receptors, suggesting an intracellular
component that binds to the C-terminus in intact cells and
stabilizes the signaling complex responsible for ERK1/2
activation [79]. Since binding of any of these adapter proteins
may mediate biased signaling, they will be described in more
detail in the following sections.
ARNO, α-actinin, and calmodulin
A possible explanation for the G protein-independent
ERK1/2 activation described above is binding of ARNO,
also named cytohesin-2, to the C-terminus of the A2AR
[73]. ARNO is a nucleotide exchange factor for the small G
proteins of the ADP-ribosylation factor (ARF) family, i.e.,
ARNO catalyzes the replacement of GDP by GTP at these
monomeric G proteins. ARNO was picked up during a
yeast two-hybrid screen and interacts with the membrane
proximal part of the C-tail of the A2AR that is forming the
intracellular helix 8. Expression of ARNO or a dominant
negative form of ARNO had no effect on the expression
levels of the A2AR, the affinity of the inverse agonist
radioligand [
3H]-ZM241385 18 [80], Gαs-dependent accu-
mulation of cAMP, or receptor desensitization in HEK293
cells [73]. Activation of ERK1/2 after 5-min stimulation
with the selective A2AR/A3R agonist CGS21680 was also
not affected. However, expression of the dominant negative
mutant of ARNO inhibited sustained ERK1/2 activation
upon longer stimulation times. These effects were likely
mediated through interactions of ARNO with ARF6, since
a dominant negative mutant of ARF6 also inhibited
sustained ERK1/2 activation. Although ARNO-mediated
signaling only explains the sustained ERK1/2 activation,
and not the initial raise in ERK phosphorylation, it is a
good example of G protein-independent signal transduction
and suggests possibilities for agonists that selectively
activate this pathway.
In the example above, expression of the dominant negative
mutant of ARNO affected sustained ERK1/2 activation in
HEK293 cells, but not Gαs-mediated signaling. In contrast,
depletion of cholesterol inhibits coupling of the A2ARt oG αs
in HEK293 cells, while leaving Gαs-independent ERK1/2
activation unaffected [81]. Therefore it seems that
cholesterol-rich membrane microdomains are required for
the interaction of the A2ARw i t hG αs proteins but not for the
activation of ERK1/2. It is tempting to speculate that such a
Gαs- and cholesterol-independent ERK1/2 activation is
mediated by ARNO. A very remarkable feature of the
A2AR is its tight precoupling to the Gαs protein [82]. This
phenomenon is referred to as restricted collision coupling,
indicating that encounters between the agonist-occupied
A2ARa n dG αs proteins do not occur at random at the cell
membrane, but by keeping the interaction partners in close
proximity in microdomains. These microdomains may for
instance be cholesterol-rich lipid rafts, which would explain
the diminished interaction of A2ARa n dG αs upon depletion
of cholesterol [81]. Microdomains form an excellent plat-
form for functionally selective ligands, since in micro-
domains receptors only encounter selected G proteins that
are present in these rafts such as Gαs, but not other proteins
such as Gα15/16 or ARNO, resulting in selective responses.
One of the proteins that may be necessary for the
localization of A2ARs in microdomains is α-actinin, by
tethering the A2AR to the cytoskeleton [78]. The cytoskeletal
protein α-actinin is involved in F-actin crosslinking and was
shown to interact with the C-terminal end of A2ARs [72]. In
addition, treatment of HEK293 cells expressing the A2AR
with cytochalasin D, which causes disruption of actin
filaments and inhibition of actin polymerization, inhibits
182 Purinergic Signalling (2011) 7:171–192internalizationoftheA2AR indicating a functional relationship
between A2ARs and the underneath actin structure [72]. That
the interaction of A2ARs with the cytoskeleton via α-actinin
may be physiologically important was shown in rat neo-
striatal neurons, which express the A2ARe n d o g e n o u s l y[ 83].
Activation of A2ARs by CGS21680 inhibits an NMDA-
induced current in these neurons. The A2AR-mediated
inhibition of this current was abolished upon treatment with
cytochalasin B that enhances actin depolymerization, indicat-
ing an important interaction between the A2AR and the
cytoskeleton which may be mediated by α-actinin. In
addition to cytochalasin B, application of the calmodulin
antagonist W-7 eliminated the A2AR-mediated inhibition of
NMDA-induced current in rat neostriatal neurons [83]. Using
several other inhibitors of signal transduction components,
the authors found that A2AR-mediated inhibition of NMDA
channels occurs via a pathway involving PLC/inositol 1,4,5-
trisphosphate/calmodulin and calmodulin kinase II.
Remarkably, one of these signaling components, calmod-
ulin, was recently shown to interact directly with the C-
terminus of A2ARs [77, 84]. Calmodulin is an intracellular
Ca
2+-binding protein that plays a central role in Ca
2+
signaling and binds the A2AR at the membrane proximal
domain including part of helix 8. When the A2ARa n d
calmodulin were coexpressed in HEK293 cells, it was found
that changes in intracellular Ca
2+ lead to conformational
changes in the calmodulin-A2AR heterodimer. In addition to
calmodulin, A2ARs have been reported to heterodimerize
with other GPCRs such as the dopamine D2R[ 14, 28, 85].
Calmodulin appears to interact with the A2AR-D2Rd i m e rt o
form a calmodulin-A2AR-D2R oligomer [84]. Even though
changes in intracellular Ca
2+ lead to a conformational change
in the calmodulin-A2AR complex, variations in intracellular
Ca
2+ did not lead to modified ERK1/2 phosphorylation after
activation of the A2AR with CGS21680. In contrast, upon
cotransfection of the D2R, an increase in intracellular Ca
2+
negatively influenced the ability of the calmodulin-A2AR-
D2R oligomer to activate ERK1/2 upon stimulation with
CGS21680, while positively modulating ERK1/2 activation
after stimulation with the D2R agonist quinpirole [84].
Therefore it seems that calmodulin modulates ERK1/2
activation initiated by the calmodulin-A2AR-D2Ro l i g o m e r ,
but not that of the calmodulin-A2ARh e t e r o d i m e r .
ARNO, α-actinin, and calmodulin all bind to the same
domain at the A2AR C-terminus that includes part of helix
8, and it is unlikely that they do so simultaneously [78].
These adapter proteins may therefore interact with the
A2AR at specific time points during receptor activation, or
depending on their availability in the cellular background. It
can also be envisioned that certain ligands stabilize receptor
conformations that favor binding of one of these adapter
proteins over the others, resulting in a ligand-dependent
activation of for instance ERK1/2.
NECAB2 and TRAX
In addition to calmodulin, another Ca
2+-binding protein was
shown to interact with the C-terminus of the A2AR. NECAB2
is a neuronal protein that was picked up during a yeast two-
hybrid screen with the A2AR C-tail as bait [76]. Increasing
concentrations of Ca
2+ inhibited the binding of the A2ARt o
NECAB2. Coexpression of NECAB2 and A2ARs in HEK293
cells resulted in a decrease in A2AR cell surface expression in
combination with intracellular retention of the A2AR.
Stimulation of cells expressing the A2AR alone with the
agonist CGS21680 resulted in a time-dependent decrease in
cell surface expression of the receptor. Intriguingly, when the
A2AR and NECAB2 were coexpressed, CGS21680-treatment
for 2 h resulted in a marked increase in cell surface
expression of A2ARs. In addition, coexpression of NECAB2
and A2ARs significantly potentiated ERK1/2 activation after
incubation with CGS21680 [76]. These results illustrate once
more how binding of intracellular proteins to the C-terminus
of the A2AR can influence signaling. The observation that
increasing Ca
2+ concentrations disrupt the interaction be-
tween the A2AR and NECAB2 suggests a dynamic fine-
tuning of A2AR signaling by NECAB2, similar to the Ca
2+-
dependent regulation of ERK1/2 activation by the
calmodulin-A2AR-D2Ro l i g o m e r[ 84].
Finally, interaction of the A2AR C-terminus with TRAX
has been reported. It rescues the nerve growth factor (NGF)-
induced differentiation process impaired by inactivation of
the transcription factor p53 in rat adrenal pheochromocytoma
PC-12 cells, which are used as a model system for neuronal
differentiation [75]. NGF induces neuronal differentiation in
PC-12 cells via multiple pathways, such as the ERK1/2 and
p53/p21 pathway. When the ERK1/2 pathway is blocked,
stimulation of the A2AR can rescue neuronal differentiation
via a cAMP/PKA/CREB-dependent pathway in PC-12 cells
[86]. However, A2AR-mediated rescue of the differentiation
process when p53 signaling was blocked was found to be
independent of PKA and to be mediated by TRAX [75].
TRAX binds to several proteins, among which translin and
the kinesin heavy chain member KIF2A. KIF2A but not
translin was shown to mediate the rescue effect of the A2AR
upon p53 impairment in PC-12 cells and primary rat
hippocampal neurons [87]. Therefore rescue of a damaged
p53 pathway, which may occur pathologically, is mediated
through an A2AR/TRAX/KIF2A pathway and may contribute
to the neuronal protective effects of A2ARs. Since p53,
TRAX, and KIF2A have been implicated in schizophrenia
and the A2AR is a potential target for the treatment of
schizophrenia [87], it can be speculated that selective
activation of the A2AR/TRAX pathway by biased agonists
may be beneficial in the treatment of schizophrenia.
Summarizing, although the A2AR has much potential for
G protein-independent signaling pathways through its
Purinergic Signalling (2011) 7:171–192 183extraordinary long carboxyl terminus, to date specific
regulation of these pathways by biased ligands has not
been reported.
A2B adenosine receptors
The A2BR is described mainly as a Gαs-coupled 7TMR [22],
although coupling to G proteins of the Gαq class has also
been described [88–90]( F i g .4). In the Jurkat T cell leukemia
cell line, Ca
2+ responses were partially sensitive to PTX,
suggesting coupling to Gαi proteins as well [91]. In
transfected CHO cells, A2BR activation resulted in ERK1/2
activation that was slightly lower than ERK1/2 activation by
the A2AR and considerably lower than by A1Rs or A3Rs [27].
The non-selective agonist NECA stimulated ERK1/2 phos-
phorylation via all four adenosine receptors with nanomolar
potencies, but the potency of NECA in CHO-A2B cells for
stimulating ERK1/2 (19 nM) was over 70-fold higher than
for cAMP accumulation (1.4 μM). Stimulation of the A2BR
with NECA in CHO cells resulted in cAMP-mediated
activation of the MAPK p38 as well, with an EC50 value
similar to that of ERK1/2 activation [92]. However, the
pathways downstream of cAMP are different, i.e., ERK1/2
activation was mediated via PI3K, while p38 phosphorylation
depended on PKA activity in CHO cells [92]. In human
umbilical vein endothelial cells (HUVECs) ERK1/2 activa-
tion was Gαs/cAMP mediated and not dependent on PKC,
making it unlikely that Gαq or Gαi proteins are involved in
this pathway [93].
Based on cAMP measurements it has previously been
assumed that the A2BR is only activated at very high,
pathophysiological concentrations of adenosine, while the
other three receptors are activated at physiological concen-
trations of adenosine. The discrepancy between potency for
the cAMP and ERK1/2 pathways indicates that amplification
of the ERK1/2 signal takes place, or that A2BR preferentially
activates the ERK1/2 pathway over Gαs.
G protein-independent interactions
One of the non-G proteins that have been described to interact
withtheA2BR is the receptor for netrin-1, also called deleted-
in-colorectal-cancer (DCC) [94]( F i g .4). Netrins are secreted
proteins that are important in axon guidance. Interaction of
the netrin-1 receptor DCC with the C-terminus of the A2BR
was found during a yeast two-hybrid screen, using the
intracellular domain of DCC as bait. Interestingly netrin-1,
the ligand for DCC, was shown to activate A2BRs directly as
well, apparently acting as a positive modulator at a site
different from the binding site of the agonist NECA [94].
Netrin-1 increased binding of
3H-NECA to A2BR-transfected
HEK293T cells in a concentration-dependent manner, which
is an indication of allosteric modulation of A2BRb yn e t r i n - 1 .
In HEK293Tcells transfected with the A2BR, both addition of
NECA and coexpression of the secreted protein netrin-1
resulted in increased cAMP levels. When NECA was added
to HEK293T cells coexpressing both the A2BR and netrin-1,
an additive effect of NECA and netrin-1 on cAMP
accumulation was observed. Similarly, in the DCC-deficient
adenocarcinoma HCT8/S11 cell line simultaneous addition of
NECA and netrin-1 resulted in additive pro-invasive activity,
although no significant additive effects on cAMP generation
were observed [95]. This suggests that netrin-1 may act as an
allosteric modulator of A2BR-mediated pro-invasive activity
but not cAMP accumulation, or that netrin-1 and A2BRs
activate distinct but convergent signaling pathways to induce
invasion in HCT8/S11 cells. It was found that the A2BRi s
directly involved in netrin-1-dependent outgrowth of dorsal
spinal cord axons [94], a finding that later was disputed by
another group [96]. A direct interaction of netrin-1 with the
A2BR was also suggested to be involved in the modulation of
transepithelial migration of polymorphonuclear neutrophils
(PMNs) [97]. In PMNs, the A2BR antagonist PSB1115 19
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Fig. 4 Potential for functional selectivity of the adenosine A2B receptor.
Similar to the A2AR no functionally selective ligands have been
identified for the A2BR. Besides coupling of the A2BR to Gαs, coupling
to Gαq/11 and possibly Gαi proteins has been described. ERK1/2 is
activated with a remarkably higher potency than observed for Gαs-
mediated cAMP accumulation, indicating divergent signal transduction
pathways that potentially can be regulated with biased ligands.
Interaction with the extracellular proteins ADA a n dn e t r i no rw i t ht h e
membrane-bound netrin-receptor DCC may influence A2BRs i g n a l i n gi n
an allosteric manner. In addition, DCC and A2BR both bind the
intracellular proteins ezrin and NHERF-2 that may be involved in
anchoring A2BR to the cytoskeleton and/or forming a signaling
complex. See references in the text for more detailed information
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indicating that netrin-1 directly interacts with A2BRs [97].
Others reported that the A2BR does not bind netrin-1, but
that A2BR activity by itself can regulate axonal responses to
netrin-1 [98]. Activation of the A2BR by the agonists
MECA 20 and NECA or by A2BR overexpression was
found to be responsible for downregulation of another
netrin-1 receptor named UNC5A, thereby modulating
netrin-1 responses [98]. Additional support for an interac-
tion between the netrin-1 receptor DCC and A2BRs is the
fact that they interact with the same proteins. DCC was
shown to interact with ezrin, a PKA-anchoring protein that
is associated with the actin cytoskeleton [99]. Interestingly,
the human A2BR also associates with ezrin upon activation
with adenosine, as well as with NHERF-2 (Na
+/H
+
exchanger regulatory factor 2) [100]. It was suggested that
the A2BR may be anchored to the membrane by NHERF-2,
and form a signaling complex with ezrin, adenylate cyclase,
and PKA [100]. Through its interaction with ezrin, DCC
may also be part of this complex. In contrast, the rat A2BR
co-immunoprecipitates with NHERF-1 and this interaction
is reduced upon activation with the agonist NECA [101].
Overexpression of NHERF-1 inhibited internalization of rat
A2BRs and a role for this scaffolding protein in rat A2BR
recycling has been proposed [101].
Taken together, there is evidence that the A2BRi si n v o l v e d
in netrin-1 signaling. It is however not clear if this occurs
through a direct interaction of netrin-1 and the A2BR, the
involvement of an A2BR/DCC/netrin-1 complex or A2BR-
mediated modulation of netrin-1 receptor expression levels.
If netrin-1 or DCC indeed acts as allosteric modulators of
A2BRs [94], it may well be possible to influence such a
complex with functionally selective ligands.
Furthermore,the A2BR has been described to interact with
proteins involved in desensitization, internalization, and
intracellular trafficking, such as β-arrestin-1 and β-arrestin-
2[ 102, 103], vesicle-associated membrane protein [104]a n d
soluble NEM-sensitive factor attachment protein [104]. An
intact C-terminal PDZ motif of the rat A2BR was found to be
important for β-arrestin-1 and clathrin-mediated internaliza-
tion, while disruption of this motif did not affect dynamin-
dependent internalization [101]. This stresses the importance
of the interaction of the intracellular tail of the A2BRw i t h
adapter proteins and the possible opportunities to intervene
in these processes with functionally selective ligands.
Besides protein–protein interactions with the intracellular
domain of the A2BR, the extracellular parts of A2BRs were
shown to bind to ADA [105], similar to the findings for the
A1R[ 52, 53]. Whereas cell surface expression of endoge-
nous ADA is not detectable on control CHO cells,
transfection of CHO cells with the A2BRr e s u l t si n
extracellular expression of ADA [105]. Total binding of
3H-NECA to CHO cells transfected with the A2BRw a s
concentration-dependently enhanced by addition of ADA,
and the affinity of NECA was increased in the presence of
ADA. In addition, cAMP production by NECA was
increased as well in the presence of ADA. These results
point toward an allosteric modulation of A2BRs by ADA,
similar as was found for the interaction of ADA with the
A1R[ 54].
Despite the apparent potential of A2BRs to engage
functional selectivity through activation of different classes
of G proteins, interactions with β-arrestins or allosteric
modulation at intracellular and extracellular sites, no
ligands have been reported that selectively employ these
pathways.
A3 adenosine receptors
A3Rs couple primarily to proteins of the Gαi class (Gαi2
and Gαi3) and to a lesser extent to Gαq/11 [106]. Signaling
by A3Rs in A6 renal epithelial cells is PTX insensitive and
was suggested to be mediated by Gαs proteins [107]
(Fig. 5).
The A3R has been described as enigmatic, in the sense
that many of the effects ascribed to A3Rs are contradictory,
such as neuroprotection vs. neurodegradation, cardiopro-
tection vs. cardiotoxicity, anti-inflammatory vs. proinflam-
matory, immunosuppression vs. immunostimulation and
pro- vs. anti-apoptotic effects [108]. In addition, there are
quite some remarkable differences in expression, sequence
homology and affinity of ligands between human and
rodent A3Rs, complicating thorough characterization of
these receptors.
The A3R contains a potential nuclear localization motif
in its intracellular helix 8, suggesting that the receptor may
interact with proteins involved in nuclear transport [109].
A3Rs on the nuclear membrane may be activated by
intracellular adenosine and interact with nuclear G proteins
or nuclear β-arrestin-1. Although nuclear expression of
A3R has to be experimentally validated, signaling by
intracellular receptors is a possible new area where
functionally selective ligands may be of use [110].
Biphasic effects at high agonist concentrations
The effects of A3R-specific agonists such as IB-MECA 21
and Cl-IB-MECA 22 on proliferation have been described
as being biphasic, e.g., preventing apoptosis at low (1 μM)
concentrations, and inducing apoptosis at very high (10–
100 μM) concentrations [111, 112] (Fig. 5). Biphasic
stimulation of ERK1/2 was also observed in the mouse
N13 microglia cell line, where low concentrations of Cl-IB-
MECA or NECA stimulated ERK1/2 phosphorylation in a
PTX-sensitive manner, while higher concentrations
Purinergic Signalling (2011) 7:171–192 185(≥10 μM) were without effect [113]. Also, Cl-IB-MECA
inhibited proliferation and ERK1/2 phosphorylation in
A375 human melanoma cells at high (10 μM) concen-
trations [114]. Such a biphasic effect was not observed
when A3R-transfected CHO cells were stimulated with
increasing concentrations of NECA, which resulted in a
sigmoidal increase in ERK1/2 activation [27, 115]. It is
therefore unclear if the observed biphasic signals should be
contributed to the stimulation of another pathway by A3Rs
at higher agonist concentrations, to rapid desensitization of
the receptor at higher agonist concentrations, non-selective
activation of other adenosine receptors or other pathways,
or a combination of the above.
There however is evidence that the effects of high
concentrations of certain A3R agonists are A3Ri n d e p e n -
dent. For instance, in the human papillary thyroid
carcinoma NPA cell line the agonist Cl-IB-MECA
inhibited cell growth at high concentrations with an IC50
of 38 μM[ 116]. ERK1/2 phosphorylation was rapidly
r e d u c e db y4 0μM Cl-IB-MECA and this effect was not
blocked after preincubation with the antagonists MRS1523
23 (10 μM) or FA385 24 (5 μM). Similar anti-proliferative
effects of high concentrations of Cl-IB-MECA (30 μM)
were reported in human leukemic cell lines HL-60 and
MOLT-4 in the presence of the antagonists MRS1523 23
(10 μM) or MRS1220 25 (5 μM) [117]. An A3R agonist
that is structurally related to Cl-IB-MECA, the ring-
constrained N-methanocarba nucleoside MRS1898 26
[118], did not induce apoptosis at high micromolar
concentrations [117]. In addition, IB-MECA (100 μM)
suppressed proliferation in a variety of human breast
cancer cells which do not have detectable levels of A3R
mRNA, while incubation with Cl-IB-MECA (100 μM)
killed the cells [119]. Adenosine 1 and several adenosine
analogs such as 3′dA (Cordycepin) 2, 2CdA (Cladribine)
3, and CADO 4 also inhibited growth of human breast
cancer cells [119]. These findings suggest that the anti-
proliferative effects of high concentrations of certain A3R
agonists such as IB-MECA and Cl-IB-MECA are A3R-
independent and may be specific to a certain class of A3R
agonists and/or cancer cells. Therefore, these biphasic
effects are likely not indicative of biased signaling at
higher concentrations of agonists.
Antagonist-mediated effects
Surprisingly, incubation of human HL-60 leukemia or U-
937 lymphoma cell lines with relatively low concentrations
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Fig. 5 Functional selectivity of the adenosine A3 receptor. Ligands with
ab i a st o w a r d sβ-arrestin-mediated signaling versus a Gαi-dependent
pathway have been identified. Ligands that are antagonists for Gαi-
mediated cAMP inhibition such as DMPA, CCPA, MRS1760,a n d
MRS542 act as partial agonists for β-arrestin translocation. Interestingly,
amongst the compounds that act as full agonists for both pathways, i.e.,
NECA, MRS3558, IB-MECA, Cl-IB-MECA, CGS21680,a n dCPA,b o t h
the nonspecific agonist NECA and the A3R-specific agonist MRS3558
show faster β-arestin translocation rates. DBXRM, a full agonist for the
Gαi pathway, was a partial agonist for β-arrestin signaling. Besides
these evident examples of functional selectivity, there are conflicting
reports of the effects A3R ligands have on apoptosis and proliferation.
Since in many of these studies very high ligand concentrations were
used, care must be taken when drawing conclusions about biased effects
on cell growth. See references in the text for more detailed information
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(0.5 μM) or MRS 1220 25 (10 nM) resulted in reduced cell
growth and apoptosis, which were reversed by addition of
low concentrations of agonists [120]. A more recent study
showed anti-proliferative and apoptotic effects of an
antagonist at high concentrations (30–50 μM) in T24
human bladder cancer cells [121]. This truncated analog
of Cl-IB-MECA, named truncated thio-Cl-IB-MECA 30,
induced cell cycle arrest and regulation of several cell cycle
and apoptosis related proteins, ERK1/2 and JNK at 50 μM.
With the use of pharmacological inhibitors a role for ERK1/
2a n dJ N Ki nA 3R-antagonist induced apoptosis was
implicated [121]. The fact that antagonists induced apopto-
sis suggests that there is a basal tone of the receptor, either
because of constitutive activity or endogenous adenosine.
This observation may also be an indication of functional
selectivity, where the “antagonists” activate other pathways
than the prototypical agonists. The latter option however is
less likely because three antagonists (MRS1220 25,
MRS1191 28, and L-249313 29) of different chemical
classes showed the apoptotic effect in the same study [120].
Functional selectivity of A3 adenosine receptors
Clear evidence for functional selectivity of A3R ligands at the
human receptor was provided by Gao et al. [122]. This group
compared ligand-induced efficacy of PTX-insensitive β-
arrestin translocation with previously reported efficacies for
the Gαi-mediated inhibition of cAMP. They used CHO
PathHunter
TM cells that express a modified A3Rw i t haC -
terminally fused enzyme fragment and β-arrestin fused to an
N-terminal deletion mutant of β-galactosidase. Upon stimu-
lation of the A3R the engineered β-arrestin interacts with the
enzyme fragment linked to the A3R, resulting in the
formation of a functional β-galactosidase enzyme that
converts a substrate into a detectable signal. Most of the
tested compounds that were full agonists at the Gαi pathway
such as CPA 5, NECA 8, CGS21680 17,I B - M E C A21,C l -
IB-MECA 22, and MRS3558 27 acted as full agonists in the
β-arrestin assay as well (Fig. 5). The rates of A3R
translocation induced by NECA 8 and MRS3558 27 were
higher than those of IB-MECA 21 and Cl-IB-MECA 22,
whilst the efficacy for β-arrestin translocation of all these
compounds was 100%. In addition to the rate of β-arrestin
translocation, the efficacy of NECA 8 for Ca
2+ mobilization
was also higher than that of Cl-IB-MECA 22, indicating
substantial differences in the mode of action of these ligands.
Most interestingly, several compounds that acted as
antagonists in the cAMP assay amongst which DPMA 31,
CCPA 32, MRS1760 33,a n dM R S 5 4 234 were partial
agonists for β-arrestin recruitment (Fig. 5). This is a clear
indication that these ligands are functionally selective at the
A3R. The opposite, i.e., full agonism for β-arrestin versus
partial agonism or antagonism for the Gαi-mediated path-
way, was not observed for any of the compounds tested.
Activation of ERK1/2 by the A3Ri nt h eC H O
PathHunter
TM cells was completely Gi-mediated, as was
previously shown for A3R-mediated responses in CHO
cells [123]. This indicates that β-arrestin-mediated signal-
ing is not involved in ERK1/2 activation in CHO cells.
DBXRM 35, which was a full agonist for the Gαi-mediated
pathway, behaved as a partial agonist for β-arrestin
recruitment, another indication of engagement of function-
ally selective pathways by A3R ligands. In order to
determine if the difference in efficacy of DBXRM has
functional consequences, CHO Pathhunter
TM cells were
desensitized for 24 h with DBXRM 35 (full agonist for Gαi
and a partial agonist for β-arrestin) or with IB-MECA 21
(full agonist at both pathways) and ERK1/2 activation by
the full agonist MRS3558 27 was determined. Cells
incubated with DBXRM 35 showed higher ERK1/2
activation (less desensitization) than cells desensitized with
IB-MECA 21, indicating that activation of the β-arrestin
pathway is involved in A3R desensitization in these cells.
The rat A3R was shown to redistribute a GFP-tagged
version of β-arrestin-2 to small punctuate spots located both
near the plasma membrane and within the cytoplasm after
stimulation with R-PIA in CHO cells [40]. However, there
was no significant overlap of β-arrestin-2 and the rat A3R. In
contrast to these findings, when rat basophilic leukemia
(RBL-2H3) cells, which express high levels of the rat A3R,
were stimulated with NECA no changes in the distribution of
β-arrestin-1 or β-arrestin-2 were observed [124].
ItisnoteworthythattheinternalizationrateofratA3Rs was
found to be dependent on cysteine residues C302 and C305
downstream of helix 8 in the carboxyl terminus of the
receptor that are thought to anchor the carboxyl terminus to
the membrane through palmitoylation [40]. When these
cysteines were mutated to alanines that cannot undergo
palmitoylation, the rat A3R underwent more rapid internal-
ization upon stimulation with R-PIA. The same study also
showed that internalization is critically dependent on three
C-terminal GRK phosphorylation sites. Moreover, mutation
of the cysteine residues to alanine resulted in a basal
phosporylation of the rat A3R[ 125]. Since receptor
phosphorylation, β-arrestin recruitment, and internalization
usually are highly dependent upon each other, one could
speculate that the faster rates of β-arrestin translocation
induced by NECA and MRS3558 compared to IB-MECA
and Cl-IB-MECA [122] reflect different conformations of
the C-terminus of the receptor induced by these compounds,
which allow faster phosphorylation and/or interaction with
β-arrestin. Another possibility is that these functionally
selective agonists differentially promote palmitate removal,
resulting in a receptor that is more susceptible to phosphor-
ylation and interaction with β-arrestins.
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Functional selectivity of synthetic ligands has been convinc-
ingly shown for the A1Ra n dA 3R. In case of the A1R, ligands
induced differential coupling to G proteins, whereas A3R
ligands can selectively activate either G protein or β-arrestin
pathways. All adenosine receptors have been shown
to interact with proteins additional to G proteins such as
β-arrestins or other scaffold proteins. Since binding of
cytosolic scaffold proteins to the intracellular domains of
7TMRs is expected to induce distinct conformations that
theoretically can lead to a functionally selective response via
these adapter proteins, it is remarkable that biased signaling
through scaffold proteins has not been observed to date for
adenosine receptors. Especially, the A2AR binds a wide
variety of scaffold proteins and would be expected to be able
to mediate a functionally selective response through these
proteins. However, many of the studies described in this
review that investigated G protein-independent signal trans-
duction used only the classical subtype-selective agonists, or
promiscuous ligands such as NECA. This is particularly true
for studies investigating novel pathways such as those
mediated by scaffold proteins. The assays deployed to study
alternative G protein-independent pathways are often tedious
and not readily suitable for the screening of compound
libraries. This may have contributed to the lack of data
describing functional selectivity mediated by scaffold proteins.
Although there are several examples where stimulation with
an agonist enhances the interaction of a given GPCR with a
scaffold protein other than β-arrestin [7], to our knowledge
there are no cases where this leads to a truly biased response.
This makes one wonder if the theoretical mechanism of biased
responses through scaffolding proteins other than β-arrestins
is physiologically relevant, or is just overlooked because it has
not been tested so far.
Functional selectivity is a relatively new phenomenon,
due to the fact that the experimental techniques needed to
distinguish between signal transduction pathways became
only recently available. In classical organ bath experiments
where contraction of a tissue is used as final and integrated
readout of agonistic signaling, differential signaling be-
tween G protein and β-arrestin went unnoticed. Only with
the use of sensitive cellular assays and molecular biology it
became possible to study the individual signal transduction
p a t h w a y st h a tm a yl e a dt oaf i n a lr e s p o n s es u c ha s
contraction of a tissue. Surprisingly, the new method of
choice to identify novel biased ligands may be a technique
that relies on studying an integrated response after all,
instead of individual pathways. In this case, the readout is a
change in cellular morphology upon 7TMR-mediated
signaling, caused by rearrangements of the cytoskeleton.
The altered morphology can be detected using label-free
techniques such as variation in cellular impedance [126].
Label-free techniques nowadays are sensitive enough to
distinguish between G protein families and eliminate the
need to perform multiple assays in order to detect divergent
signaling pathways.
Since the discovery of adenosine receptors, a large array
of synthetic agonists, inverse agonists, antagonists, and
allosteric modulators for these 7TMRs has been reported.
Most of these compounds have only been validated using
classical second messenger assays such as stimulation or
inhibition of cAMP accumulation. It is most likely that
there will be compounds with hitherto unrecognized
functionally selective properties among this large ligand
library. The identification and characterization of these
compounds may identify new therapeutic opportunities for
old drugs.
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